The stock market was lucky to get back to breakeven, but these stocks soared. Find out why.
A win and loss for marijuana, a big advance in Alzheimer's disease, and the next big thing are among some of the market-moving things I expect to see happen this year.
Pfizer's stock is up 4% year-to-date, but this event was a clear disappointment for its shareholders in 2015.
Early human clinical trial results suggest that a better drug for lowering bad cholesterol may be on the horizon.
Calls for prescription drug reform blast the original biotech blue-chip stock in September. Could Amgen have more downside to come, or is this latest dip an early holiday gift?
Amgen and Allergan's ABP 215 biosimilar to Avastin posted positive results in phase 3 trials.
As the first generation of the cholesterol-lowering drugs hits the market, investors should already be looking at the next-generation products.
AbbVie's management team had a lot to talk about on their last investor conference call. Here are my three takeaways you need to know when considering the stock for investment.
The generic-drug market is sizzling hot. Here are three investing ideas to catch some of that heat wave.
These three companies have the potential to double their share price from current levels. Here's why.